Učitavanje...
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
SIMPLE SUMMARY: Pembrolizumab + chemotherapy and nivolumab + ipilimumab are approved first-line treatment options for patients with metastatic stage IV NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%. Understanding the differences between these treatment options is required to inform clinical de...
Spremljeno u:
| Izdano u: | Cancers (Basel) |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7762014/ https://ncbi.nlm.nih.gov/pubmed/33291810 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123648 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|